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The idea that supplemented probiotic bacteria – ‘live micro-
organisms that, when administered in adequate amounts, 
confer a health benefit on the host’ (Sanders, 2008: 58) – 
could be used as a treatment for major depressive disorder 
(MDD) was suggested, in modern times, by Logan and 
Katzman (2005). A key concept behind this review was that 
nutritional influences on depression are underestimated and 
some strains of probiotic bacteria may correct underlying 
biological factors associated with depression. Indeed, pro-
biotic strains have been shown to lower proinflammatory 
cytokines (Lin et al., 2008) and oxidative stress (Kullisaar 
et al., 2003) in humans, both of which are associated with 
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Abstract
Objectives: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low 
mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proin-
flammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment 
response.
Method: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate 
scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing 
Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks. Data were 
analysed as intent-to-treat.
Results: No significant difference was found between the probiotic and placebo groups on any psychological outcome 
measure (Cohen’s d range = 0.07–0.16) or any blood-based biomarker. At end-point, 9 (23%) of those in the probiotic 
group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 
(26%) of those in the placebo group (χ1
2 = 0 107. , p = ns). Baseline vitamin D level was found to moderate treatment effect 
on several outcome measures. Dry mouth and sleep disruption were reported more frequently in the placebo group.
Conclusions: This study found no evidence that the probiotic formulation is effective in treating low mood, or in mod-
erating the levels of inflammatory and other biomarkers. The lack of observed effect on mood symptoms may be due 
to the severity, chronicity or treatment resistance of the sample; recruiting an antidepressant-naive sample experiencing 
mild, acute symptoms of low mood, may well yield a different result. Future studies taking a preventative approach or 
using probiotics as an adjuvant treatment may also be more effective. Vitamin D levels should be monitored in future 
studies in the area. The results of this trial are preliminary; future studies in the area should not be discouraged.
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mood disorders (Ascoli et al., 2016; Dowlati et al., 2010; 
Stefanescu and Ciobica, 2012). Gut–brain axis research 
suggests that bacteria in the gastrointestinal (GI) tract also 
communicate with the central nervous system in the 
absence of an immune response (Cryan and Dinan, 2012; 
Keightley et al., 2015).
Many papers have explored the links among gut microbes, 
brain and behaviour (e.g. Collins et al., 2012; Mayer, 2011; 
Thakur et al., 2014). A number of narrative reviews suggest 
manipulation of gut microbiota composition (usually via 
ingestion of probiotic supplements) as an intervention for 
psychological outcomes (e.g. Bested et al., 2013; Cryan and 
Dinan, 2012; Dinan et al., 2013; Keightley et al., 2015). 
Dinan et al. (2013) coined the term ‘psychobiotics’ to 
describe probiotic bacteria that produces a health benefit in 
patients with psychiatric illness. However, these reviews rely 
mainly on evidence from animal studies in which certain 
probiotic strains have affected emotional behaviour and 
brain activity (e.g. Bravo et al., 2011; Messaoudi et al., 
2010). For example, Messaoudi et al. (2010) found that 
Lactobacillus helveticus and Bifidobacterium Longum – the 
probiotic strains used in this study – had beneficial effects on 
conditioned defensive burying in rats.
Tillisch et al. (2013) provided the first demonstration 
that probiotics affect brain activity in healthy humans using 
functional magnetic resonance imaging (fMRI). A recent 
systematic review found that the human research assessing 
the impact of probiotics on psychological outcomes is lim-
ited, and that the few existing human trials assessed the 
effect of various probiotic strains on mood in healthy sam-
ples only (Romijn and Rucklidge, 2015). For example, L. 
helveticus and B. longum improved mood and anxiety 
symptoms in a sample of 55 healthy participants over a 
30-day intervention period (Messaoudi et al., 2010). As all 
existing trials were in healthy human subjects, the review 
concluded that trials in populations selected for a level of 
psychological distress, or with diagnosed clinical psychiat-
ric disorders, were necessary to advance the field (Romijn 
and Rucklidge, 2015).
Since the 2015 review, Steenbergen et al. (2015) reported 
that a multispecies probiotic formulation reduced cognitive 
reactivity to sad mood significantly more than placebo in a 
healthy sample; however, there was no effect of probiotics 
on Beck Depression Inventory (BDI) scores in this study. 
Akkasheh at al. (2016) reported a group difference in BDI 
score after supplementation with probiotics or placebo, 
adjuvant to citalopram, in a sample with diagnosed MDD; 
however, this result no longer reached significance when 
controlling for confounders (Akkasheh et al., 2016).
The present trial was a randomized controlled trial test-
ing probiotic bacteria as a primary treatment for mood and 
other psychological outcomes in a sample selected for low 
mood. Based on the existing evidence from gut–brain axis 
research, and on models linking mood disorders with 
inflammation, immune activation and the state of the gut 
microbiota, the trial was designed to ascertain whether a 
specific probiotic formulation containing L. helveticus and 
B. longum – previously found to improve emotional behav-
iour in animals and psychological outcomes and humans – 
would improve psychological outcomes in our sample.
This study also aimed to examine whether the levels of 
blood biomarkers would predict or impact treatment 
response. Given the association between depression and 
inflammation, and the effects of probiotics on proinflam-
matory cytokines, we elected to measure a subset of inflam-
matory markers (interleukin [IL]-1β, IL-6 and tumour 
necrosis factor alpha [TNF-α]). Although this particular 
probiotic formulation has not been tested for effects on 
inflammatory markers, several strains of Lactobacillus 
have displayed anti-inflammatory properties in vitro in 
human intestinal epithelial cells (Wallace et al., 2003), and 
B. longum R0175 has been found to improve symptoms of 
ulcerative colitis in humans, suggesting potential anti-
inflammatory properties (Haskey and Dahl, 2009). We also 
measured brain-derived neurotrophic factor (BDNF), as a 
decrease in inflammation and oxidative stress may lead to 
increased BDNF, which is a potential factor in the develop-
ment and maintenance of depression (Berk et al., 2011). 
Emerging evidence suggests that vitamin D is an important 
modifier of the effects of the intestinal flora on inflamma-
tory processes (Ly et al., 2011), which is interesting given 
the association between vitamin D and low mood (Anglin 
et al., 2013), and could be an effect moderator in any inter-
ventional research using probiotics for low mood; we there-
fore measured blood levels of vitamin D. In addition to 
measuring biomarkers of inflammation, we also aimed to 
ascertain whether presence, severity or change in irritable 
bowel syndrome (IBS) symptoms would predict or impact 
treatment response. There is evidence of high comorbidity 
of MDD with IBS (Fond et al., 2014) suggesting some pos-
sible common factors in aetiology, such as an increase in 
systemic inflammation, which has been observed in both 
disorders (Dowlati et al., 2010; Liebregts et al., 2007). It 
was therefore anticipated that symptoms of gut disorder 
may be an important moderator of treatment response when 
testing a gut-directed intervention for mood symptoms.
Materials and methods
Design
The trial used a double-blind, randomized, placebo-controlled 
design, in which participants were assigned (1:1) to receive 
either the active probiotic or a placebo for 8 weeks. The trial 
was prospectively registered on the Australian New Zealand 
Clinical Trials Registry (Ref#: ACTRN12613000438752; 
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id
=364005&;isReview=true). No changes were made after 
trial registration was completed. The study received ethical 
approval from the national New Zealand Southern Health 
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and Disability Ethics Committee (URA/12/05/013) and the 
Human Ethics Committee of the University of Canterbury 
(HEC 2012/67).
Participants
Participants were recruited in Canterbury, New Zealand, via 
self-referral. Screening was completed using an online sur-
vey (http://bit.ly/UCnutritionresearch). If a potential partici-
pant was ineligible, they were directed to local resources for 
mental health care. Inclusion criteria were as follows: 
(1) either ⩾11 on the Quick Inventory of Depressive 
Symptomatology (QIDS-SR16) or ⩾14 on the depression 
subscale of the Depression, Anxiety and Stress Scale 
(DASS-42); (2) aged 16+ at the time of screening; and 
(3) free of any psychiatric medication for at least 4 weeks 
prior to the trial. Participants who were currently undergo-
ing regular psychological therapy were allowed to partici-
pate and continue with their therapy, provided that they had 
already been receiving therapy for 6 months or more prior to 
beginning the trial. Exclusion criteria were as follows: any 
neurological disorder; renal, hepatic, cardiovascular or res-
piratory disease; any serious medical condition with major 
medical interventions anticipated during the trial; pregnancy 
or breastfeeding; use of any supplement considered poten-
tially antidepressant (e.g. St John’s Wort, 5-HTP, SAMe); 
serious risk of suicide or violence; and current or recent pro-
biotic or antibiotic use. Participants were asked not to con-
sume any other probiotic supplements during the course of 
the trial. If an antibiotic or antidepressant course was begun 
by any patient during the course of the trial, then that patient 
was considered to have violated trial protocol.
Interventions
The test product was a probiotic formula developed by 
Lallemand Health Solutions (Mirabel, Quebec, Canada), 
which contains freeze-dried L. helveticus R0052 (strain 
I-1722 in the French National Collection of Cultures of 
Microorganisms [CNCM], Institut Pasteur, Paris, France) 
and B. longum R0175 (CNCM strain I-3470) bacteria at a 
dosage of three billion colony-forming units (⩾3 × 109 
CFU) per 1.5 g sachet. Excipients used were as follows: 
xylitol, maltodextrin, plum flavour and malic acid. Bacterial 
enumeration of the product confirmed that the sachets con-
tained ⩾3 × 109 CFU at the beginning and end of the study. 
The placebo product contained only the excipients and was 
sensorially identical to the active product. Both products 
were room temperature stable and in the form of orally dis-
persible powder in plain sachets.
Measures
Demographic information. Date of birth, ethnicity, household 
income, occupation and highest educational qualification 
were requested at screening. Occupation data were used to 
calculate a score of socio-economic status (SES) based on 
the New Zealand socio-economic index (NZSEI-06) (Milne 
et al., 2013).
Montgomery–Åsberg Depression Rating Scale. The Mont-
gomery–Åsberg Depression Rating Scale (MADRS) is a 
well-validated 10-item clinician-rated diagnostic question-
naire designed to measure the severity of depressive epi-
sodes (Montgomery and Åsberg, 1979). The maximum 
possible score is 60. Severity cut-offs used were as follows: 
none/recovered (0–8), mild (9–17), moderate (18–34) and 
severe (⩾35) (Müller et al., 2003); response was defined as 
>60% reduction in score from baseline. The patients were 
rated in person at baseline and 8 weeks.
Improved Clinical Global Impressions scale. The Improved 
Clinical Global Impressions (iCGI) scale includes two cli-
nician-rated measures that assess clinical severity on a 
7-point scale at the time of rating (severity scale, ICGI-S) 
and treatment response from baseline on a 13-point scale 
(improvement scale, iCGI-I) (Kadouri et al., 2007). The 
patients were rated at baseline and 8 weeks.
QIDS-SR16. The QIDS-SR16 is a 16-item self-rated ques-
tionnaire designed to assess the severity of depressive 
symptoms (Rush et al., 2003). Scores range from 0 to 27. 
Severity cut-offs include none (<6), mild (6–10), moderate 
(11–15), severe (16–20) and very severe (⩾21). The 
patients were rated at screening, baseline and every 2 weeks 
throughout the study.
Global Assessment of Functioning. The Global Assessment of 
Functioning (GAF) is a clinician-rated measure on which 
the social, occupational and psychological functioning of 
adults is rated from 1–100, with a higher score indicative of 
better overall functioning (Caldecott-Hazard and Hall, 
1995). The patients were rated at baseline and 8 weeks.
DASS-42. DASS-42 is a 42-item self-report questionnaire 
designed to assess current severity of symptoms relating to 
depression, anxiety and stress (Lovibond and Lovibond, 
1995). The patients were rated at screening, baseline and 
8 weeks.
Irritable Bowel Syndrome Symptom Severity Scale. Irritable 
Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a 
five 100-point sliding scale that assesses the severity and 
frequency of abdominal pain, the severity of abdominal 
distention, dissatisfaction with bowel habits and interfer-
ence with quality of life (Francis et al., 1997). Scores range 
from 0 to 500. Severity cut-offs include remission/no IBS 
symptoms (<75), mild (75–175), moderate (175–300) and 
severe (>300). The patients were rated at baseline and 
8 weeks.
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Biomarkers. Blood samples were collected at baseline and 
8 weeks to measure levels of high-sensitivity C-reactive 
protein (hsCRP), IL-1β, IL-6, TNF-α, vitamin D and 
BDNF. Testing was completed at Canterbury Health Labo-
ratories. Plasma 25 hydroxycholecalciferol vitamin D was 
measured using high-performance liquid chromatography 
(HPLC)-tandem mass spectrometry. HsCRP was measured 
using latex-enhanced nephelometry. Serum IL-1β, IL-6, 
TNF-α and BDNF were measured using commercially 
available enzyme-linked immunosorbent assays (ELISA; 
R&D Systems). For the hsCRP assays, specimens were col-
lected from patients who had not recently (within the last 
4 days) suffered illness or had overt signs of inflammation. 
HsCRP and vitamin D testing was completed immediately 
after specimen collection. For the BDNF, IL-1β, IL-6 and 
TNF-α assays, blood was centrifuged (Eppendorf 5810R 
centrifuge at 2500 rpm for 10 min) and serum aliquoted 
immediately after specimen collection and stored at −80°C 
until batch testing could be completed.
Monitoring. A checklist of common side effects associated 
with taking medications (e.g. headaches, rash, nausea) was 
used every 2 weeks to monitor for adverse events. Partici-
pants were also asked to estimate their intake of substances 
(caffeine, nicotine, alcohol and street drugs) every 2 weeks. 
Participants were asked every 2 weeks to self-report how 
many doses of the study product they had taken and missed.
Randomization and blinding
Randomization was completed by a research assistant not 
otherwise involved in the study: a table of numbers repre-
senting probiotic and placebo was randomized (1:1) in 
blocks of 10 using www.randomization.com. Sachets (pro-
biotic and placebo) were pre-packaged according to the 
randomization code. This meant that participants, clini-
cians and raters remained blind to the allocated group of 
each participant until after the database was locked and 
data analysis was completed.
Study procedure
Eligible participants attended a meeting at the University of 
Canterbury conducted by a clinical psychologist, trainee 
clinical psychologist or a trained research assistant. After 
informed consent was obtained, clinician-rated measures 
were rated based on a personal interview. Blood samples 
were collected, and participants completed self-report 
questionnaires on a computer-based survey. Participants 
were allocated to the next sequentially numbered bag. 
During the 8-week intervention period, participants were 
asked to take one sachet at the same time each day, prefer-
ably before a meal, by pouring the orally dispersible pow-
der from the sachet directly into the mouth where it rapidly 
dissolved. Participants were monitored every 2 weeks by an 
online questionnaire. The same procedure was followed at 
the final assessment.
Sample size
Due to the lack of any pilot data, the target sample size of 
40 per group was selected based on the size of similar stud-
ies in the literature and what would identify a clinically 
meaningful group difference. Randomized controlled trials 
using probiotics and assessing psychological outcomes 
typically have a sample size of 40–75 (Akkasheh et al., 
2016; Dickerson et al., 2014; Diop et al., 2008; Messaoudi 
et al., 2010). Recruiting 80 participants in total would be 
sufficient to show a moderate effect size (>0.60) for the 
comparison of probiotic and placebo as statistically signifi-
cant (two-tail α = 0.05) with 80% power.
Statistical analysis
The primary outcome measures defined a priori were the 
MADRS, the iCGI and the QIDS-SR16. IBM SPSS 
Statistics version 20 was used for all statistical analyses. 
Baseline variables were compared between treatment 
groups using t-tests, chi square tests and Mann–Whitney 
U tests. Changes from baseline to the end of treatment 
were compared using analysis of covariance (ANCOVA), 
with the baseline level as the covariate. Changes in meas-
ures (iCGI-I ratings) were compared using one-way anal-
ysis of variance (ANOVA). Efficacy analyses were 
completed by an independent statistician. The treatment 
effects were summarized by mean differences and 95% 
confidence intervals derived from the ANCOVA/ANOVA 
models. Adverse events occurring in ⩾5% of the sample 
were compared between groups using Fisher’s exact tests. 
Analyses of all psychological outcome measures were 
completed on an intention-to-treat basis. The last-obser-
vation-carried-forward technique was used to impute 
missing values. Secondary analyses were undertaken on 
all psychological outcomes using the per protocol set, 
defined as those randomized participants who took their 
allocated product for the full intervention period (⩾80% 
compliance) and did not violate the study protocol. 
Biomarker variables were analysed per protocol. Skewed 
variables were log10 transformed. Changes from baseline 
to the end of treatment were compared using ANCOVA, 
with the baseline level as the covariate. For log10 trans-
formed data, differences derived from the ANCOVA mod-
els for each treatment group were back transformed for 
display as geometric mean ratios, with the ratio of these 
used for the inter group comparison. Data for non-trans-
formed biomarker variables were summarized by mean 
differences and 95% confidence intervals derived from 
the ANCOVA models. All significance tests were two-
tailed and p-values <0.05 were considered statistically 
significant.
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Exploratory analyses. Hierarchical multiple regression was 
used to examine whether treatment response was moder-
ated by baseline levels of biomarkers. The baseline value of 
the dependent variable was entered (with any variable 
found to be correlated with biomarker levels), followed by 
experimental group and moderator variable. The interac-
tion between the predictor moderator variable and group 
was then added into the model as the critical term identify-
ing the presence of a moderating effect. Significant interac-
tion effects were examined by calculating regression slopes 
one standard deviation above and below the mean of the 
moderator; simple slope analyses were conducted to exam-
ine whether the regression slopes differed significantly 
from zero.
Results
Study population
From 203 self-referrals between May 2013 and May 2014, 
79 adults (age ⩾ 16 years) with at least moderate low mood 
completed informed consent and were assigned to the pro-
biotic group (n = 40) or placebo group (n = 39). Seven peo-
ple from the probiotic group and three people from the 
placebo group dropped out prior to finishing the trial (see 
Figure 1 for CONSORT diagram), resulting in 10 baseline 
observations being carried forward for outcome measures 
rated at baseline and 8 weeks (MADRS, CGI, GAF, DASS-
42, IBS-SSS). In addition, 8 mid-trial observations were 
carried forward on the QIDS-SR16 (taken every 2 weeks 
throughout the study). Overall, the two groups were well 
matched in baseline characteristics (Table 1). Six partici-
pants were undergoing long-term psychotherapy during the 
trial: three from the probiotic group and three from the pla-
cebo group. No participant discontinued their psychother-
apy during the trial. There was a significant imbalance in 
history of antidepressant usage, with 70% of the probiotic 
group self-reporting prior antidepressant usage compared 
with 46% of the placebo group, χ1
2 = 4 617. , p < 0.05. The 
probiotic group scored significantly higher on the IBS-SSS at 
baseline (median = 105) than the placebo group (median = 75) 
(Mann–Whitney U test), U = 558.5, Z = −2.17, p < 0.05. No 
other significant differences were found.
Psychological efficacy outcomes
Intent-to-treat analysis (n = 79) showed no significant group 
differences on any outcome measure (Table 2). Secondary 
analyses based on the per protocol sample (n = 69) yielded 
similar results, with no primary or secondary outcome 
approaching significance (data not shown). Further analyses 
controlling for history of antidepressant usage, season at 
Figure 1. CONSORT flow diagram.
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recruitment, and presence/severity of IBS at baseline 
revealed very similar results to the primary analyses, with no 
variable tested having a significant effect on any outcome. At 
end-point, 9 (23%) of those in the probiotic group showed a 
⩾60% change on the MADRS (responders), compared to 10 
(26%) of those in the placebo group (χ1
2 = 0 107. , p = ns).
Table 1. Baseline demographic and clinical characteristics of study participants (n = 79).
Characteristic Probiotic group (n = 40) Placebo group (n = 39)
Demographics
 Age, years, mean (SD)  35.8 (14) 35.1 (14.5)
 Male, n (%) 8 (20) 9 (23)
 Socioeconomic status,a mean (SD)  45.0 (11.5) 41.6 (13.2)
Education, n (%)
 No high school certificate 3 (8) 7 (18)
 Completed high school 13 (33) 10 (26)
 Post-secondary (e.g. trade certificate) 15 (38) 13 (33)
 University degree 9 (23) 9 (23)
Ethnic origin, n (%)
 New Zealanders of European descent 30 (75) 31 (80)
 NZ Maori 2 (5) 1 (3)
 Other 8 (20) 7 (18)
Clinical
Baseline MADRS score, mean (SD)  28.3 (6.1) 27.0 (6.3)
Chronic low mood,b,c n (%) 31 (78) 24 (62)
Anxiety disorder,c n (%)
 Current 20 (50) 16 (41)
 Past 21 (53) 18 (46)
Alcohol/substance misuse or dependence,c n (%)
 Current 4 (10) 1 (3)
 Past 6 (15) 8 (21)
Any co-occurring disorder,c n (%)
 Current 23 (57) 18 (46)
 Past 24 (60) 21 (54)
History of antidepressant use,c n (%) 28 (70) 18 (46)*
Current therapy,d n (%) 3 (8) 3 (8)
IBS severity,e median (IQR) 105 (53–252) 75 (28–138)*
Severity of IBS by category, n (%)
 None 16 (40) 19 (49)
 Mild 10 (25) 15 (39)
 Moderate 8 (20) 5 (13)
 Severe 6 (15) 0 (0)
MADRS: Montgomery–Åsberg Depression Rating Scale; IBS: irritable bowel syndrome; SD: standard deviation; IQR: interquartile range.
aBased on the New Zealand Socio-Economic Index 2006 (NZSEI-06) (Milne et al., 2013).
bChronic depression defined as >2 years continuous symptoms for the current episode of low mood.
cEstablished using self-report and retrospective self-report.
dCurrently receiving any form of psychotherapy (self-report) – note that must be regularly for >6 months in order to meet entry criteria.
eScore on Irritable Bowel Syndrome Symptom Severity Scale at baseline (0–500).
*Significantly different from probiotic group, p < 0.05.
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Biomarkers
Baseline blood data were available for 77 participants (pro-
biotic, n = 38; placebo, n = 39) (Table 3). In total, 58 of the 
77 participants (75%) had at least one marker of inflamma-
tion (CRP, IL-1β, IL-6 or TNF-α) elevated outside the ref-
erence range at baseline (reference ranges shown in Table 
3). There were no significant differences in biomarker lev-
els between the active treatment and placebo groups at 
baseline.
Both baseline and end-point blood data were available 
for 65 participants (probiotic, n = 29; placebo, n = 36); how-
ever, due to some test results falling outside of the range of 
the assays used, per protocol sets differed for hsCRP 
(n = 55), IL-1β (n = 63) and IL-6 (n = 62). No significant 
group differences were observed in change in the level of 
any biomarker over the intervention period (Tables 4 and 
5). Controlling for time of sample collection had no signifi-
cant effect on any biomarker outcome.
Monitoring
There were significant group differences in the number of 
occurrences of two adverse events; however, in both cases, 
there were more occurrences in the placebo group than the 
probiotic group (Fisher’s exact tests: dry mouth, p < 0.05; 
Table 2. Baseline and post 8-week data on psychological outcome measures in intent-to-treat population (n = 79).
Outcome 
variable
Probiotic Placebo
Difference [95% 
CI] p ESb d
Baseline 
mean (SD)
Post mean 
(SD)
Change 
from 
baselinea
Baseline 
mean (SD)
Post mean 
(SD)
Change 
from 
baselinea
MADRS 28.3 (6.1) 19.3 (8.9) −8.7 27.0 (6.3) 17.6 (9.5) −9.7 −1.0 [−4.9, 3.0] 0.62 0.11
iCGI-S 3.8 (0.5) 2.9 (1.1) −0.9 3.66 (0.6) 2.7 (1.0) −0.9 −0.1 [−0.5, 0.4] 0.75 0.07
iCGI-Ic 2.4 (2.2) 2.4 2.7 (2.0) 2.7 −0.3 [−1.2, 0.6] 0.52 0.16
QIDS-SR16 15.2 (3.9) 8.5 (5.5) −6.3 13.2 (3.8) 8.0 (4.8) −5.6 0.7 [−1.5, 2.8] 0.53 0.15
GAF 61.2 (5.6) 67.5 (8.5) 6.0 63.1 (5.4) 69.3 (7.1) 6.6 0.7 [−2.6, 3.9] 0.68 0.1
DASS 64.3 (23.9) 37.9 (29.0) −23.4 50.0 (20.6) 29.5 (20.8) −23.6 −0.2 [−10.6, 10.1] 0.97 0.01
 Depression 24.2 (9.1) 13.2 (11.6) −9.9 19.0 (10.5) 10.3 (8.8) −9.9 −0.03 [−4.1, 4.1] 0.99 0.003
 Anxiety 15.2 (10.4) 8.9 (9.6) −5.2 10.6 (6.6) 6.0 (6.0) −5.7 −0.4 [−3.5, 2.6] 0.78 0.07
 Stress 25.0 (9.2) 15.9 (10.4) −8.1 20.4 (8.4) 13.2 (8.3) −8.3 −0.2 [−4.0, 3.6] 0.92 0.02
ES: effect size; MADRS: Montgomery–Åsberg Depression Rating Scale; iCGI: improved Clinical Global Impression Scale (Severity/Improvement 
scale); QIDS-SR16: Quick Inventory of Depressive Symptoms; GAF: Global Assessment of Functioning; DASS: Depression, Anxiety and Stress Scale.
aAdjusted for baseline.
bCohen’s d effect size: measured as the mean difference in change divided by the pooled standard deviation of the change, based on values adjusted 
for baseline.
cAssesses change only, therefore not measured at baseline.
Table 3. Baseline biomarker levels for all participants for whom baseline blood data were available (n = 77).
Biomarker
Sample with baseline blood data (n = 77)
GM Range
Deficient (below 
reference range): n (%)
Elevated (above 
reference range): n (%)
CRP (mg/L), reference range: 0–3 1.6 0.2–37.3 NA 23 (30)
IL-1β (pg/mL), reference range: 0–0.201 0.2 0–1.7 NA 49 (64)
IL-6 (pg/mL), reference range: 0.447–9.960 1.9 0.4–10.0 2 (3) 3 (4)
TNF-α (pg/mL), reference range: 0.550–2.816 0.9 0.1–3.6 14 (18) 4 (5)
BDNF (ng/mL), reference range: 6.2–42.6 25.3 5.2–48.2 1 (1) 2 (3)
Vitamin D (nmol/L), reference range: 50–150 52.7 11–119 31 (40) 0 (0)
Abbreviations: GM = geometric mean; CRP = C-reactive protein; IL = interleukin; TNF = tumor necrosis factor; BDNF = brain derived neurotrophic 
factor.
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sleep disruption, p < 0.05). The rates of all other adverse 
events did not differ between the groups (Table 6). There 
were three serious adverse events over the course of the 
trial, all of which were suicide attempts by one participant 
from the placebo group. There were no serious adverse 
events in the probiotic group.
Overall, adherence to the study protocol was good, with 
97% of required doses taken as measured by post-study 
sachet counts. There was no significant difference in compli-
ance rates between groups (number who took a minimum of 
95% of required doses; χ1
2 0 004= . , p = ns). During the study 
period, there were no group differences in rates of alcohol 
misusers (defined as more than two standard drinks per day 
for women and three standard drinks per day for men; n = 4 
[10%] for probiotic group, n = 2 [5%] for placebo group; 
p = ns), smokers (n = 8 [20%] for probiotic group, n = 10 [35%] 
for placebo group; p = ns) or cannabis users (n = 6 [15%] for 
probiotic group, n = 3 [10%] for placebo group; p = ns).
Exploratory analyses
We examined baseline biomarker levels as possible mod-
erators of treatment effect to attempt to provide insights in 
this very new area of research. Two participants were 
excluded from the analyses as they did not provide baseline 
blood data. Significant interaction effects were found 
between vitamin D and group on several outcome meas-
ures. The interaction between group and vitamin D 
explained significant amounts of variance in iCGI-S 
(ΔR2 = 0.07, p < 0.05), QIDS-SR16 (ΔR2 = 0.05, p < 0.05) 
and GAF (ΔR2 = 0.06, p < 0.05) scores over and above the 
baseline value of the dependent variable, season at time of 
recruitment (control variable), and the main effects of 
group and vitamin D. Simple slope analyses revealed that 
the association between baseline vitamin D and change on 
these measures was significant for the probiotic group 
(iCGI-S, b = 0.017, t = 2.26, p < .05; QIDS-SR16, b = 0.082, 
t = 2.60, p < 0.05; GAF, b = −0.124, t = 2.66, p < 0.05) but not 
for the placebo group (iCGI-S, b = −0.005, t = 0.76, p = ns; 
QIDS-SR16, b = −0.002, t = 0.07, p = ns; GAF, b = 0.022, 
t = 0.47, p = ns). Among those randomized to the probiotic 
group, those who had high vitamin D at baseline showed 
greater improvement in mood and functioning than those 
who had low vitamin D at baseline.
Discussion
Existing evidence suggests that depression is associated 
with increased permeability of the gut wall (Maes et al., 
2012), increased immune and inflammatory activation 
Table 4. Baseline to post 8-week biomarker levels in per protocol population using log10 transformed data.
Biomarker (n; active 
treatment:placebo)
Probiotic Placebo GM ratiob
pcGM ratioa GM ratioa Probiotic vs placebo [95% CI]
CRP (55; 24:31) 0.83 0.88 0.93 [0.72, 1.57] 0.75
IL-1β (63; 27:36) 0.86 0.85 1.02 [0.53, 1.82] 0.95
IL-6 (62; 29:33) 1.10 0.93 1.20 [0.66, 1.05] 0.12
TNF-α (65; 29:36) 1.09 1.09 1.01 [0.70, 1.40] 0.96
GML: geometric mean; BL: baseline; CRP: C-reactive protein; IL: interleukin; TNF: tumour necrosis factor; ANCOVA: analysis of covariance.
aPost:pre. Based on log10 scale; back transformed for display.
bBased on log10 scale, adjusted for baseline and back transformed.
cSignificance value derived from the ANCOVA models based on log10 scale.
Table 5. Baseline to post 8-week biomarker levels in per protocol population.
Biomarker (n; active 
treatment:placebo)
Probiotic Placebo
Difference 
[95% CI] p ESb d
Baseline 
mean (SD)
Post mean 
(SD)
Change 
from BLa
Baseline 
mean (SD)
Post mean 
(SD)
Change 
from BLa
Vitamin D, nmol/L 
(65; 29:36)
57.7 (22.1) 57.1 (21.8) −1.16 60.4 (24.3) 57.1 (23.0) −2.90 1.71 [−6.79, 
10.20]
0.69 0.10
BDNF, ng/mL  
(64; 28:36)
27.6 (9.0) 27.7 (6.2) 0.95 25.7 (6.3) 25.6 (8.9) −0.79 1.75 [−2.16, 
5.66]
0.38 0.23
SD: standard deviation; BL: baseline; BDNF: brain-derived neurotrophic factor.
aAdjusted for baseline.
bCohen’s d effect size: measured as the mean difference in change divided by the pooled standard deviation of the change, based on values adjusted 
for baseline.
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(Berk et al., 2013; Maes, 2011) and gut disorders such as 
IBS (Fond et al., 2014). These underlying biological factors 
support a proposal made by Logan and Katzman (2005) 
that probiotics could be used as a treatment for depression. 
This study aimed to undertake preliminary testing of probi-
otics as a treatment for low mood. The lack of effect of 
probiotics on psychological outcomes in the present study 
is perhaps not surprising given the incipient nature of this 
area of research. There are many possible reasons for the 
lack of effect; some signals from our exploratory analyses 
may help to break some ground in this field.
First, it is possible that the findings of this study are 
restricted by the length of the intervention period or sample 
size. To our knowledge, the only previous trial to have 
assessed mood outcomes after probiotic administration in a 
symptomatic sample is a trial by Akkasheh et al. (2016), 
which reported positive effects of probiotics on BDI scores 
compared with placebo (although this effect was attenuated 
by confounders) in a sample of 40 participants over 8 weeks; 
however, this trial used probiotics as an adjuvant treatment 
alongside citalopram. It is possible that probiotics would 
take longer than 8 weeks to effect changes in mood when 
used as a primary treatment in a symptomatic sample, as in 
the present study. Given that most modern antidepressant 
studies have reported effect sizes of 0.2–0.4 (Vöhringer and 
Ghaemi, 2011), it is likely that our study was underpowered 
to detect an effect of probiotics. However, we think it 
unlikely that the lack of any observable group difference in 
this study was an issue of power alone, given the remarka-
bly similar change in outcomes in both groups (p-value 
range = 0.52–0.99). To detect a change at this level would 
have required a sample of thousands, which would have 
produced a clinically irrelevant result. In addition, a mar-
ginally bigger change was observed in the placebo group 
than the probiotic group on several outcome measures, 
which also argues against the lack of observed effect being 
an issue of power alone. We therefore consider that there 
were probably multiple factors responsible for the lack of 
observable effect.
The lack of effect on inflammatory markers is somewhat 
unexpected given the elevated inflammatory profile of our 
sample, and given the probable anti-inflammatory effects 
of some probiotics, including some Lactobacillus strains 
and B. Longum (Haskey and Dahl, 2009; Wallace et al., 
2003). It is possible that these tests were underpowered and 
may have reached significance in a larger sample. In addi-
tion, although we controlled for time of sample collection 
in our analyses, it would have been preferable to collect 
samples at the same time for each participant.
The severity and chronicity of the current sample is 
another consideration: mean baseline MADRS score in the 
present sample was high in the moderate range and almost 
70% of the sample reported continuous low mood lasting 
more than 2 years. It is possible that probiotics may be more 
effective in shorter term or in less severe low mood. 
Baseline severity and chronicity were not reported by 
Akkasheh et al. (2016), so no comparison can be drawn.
Recruiting participants not currently receiving pharma-
cological treatment for their low mood was intended to pro-
vide insight into the efficacy of probiotics as a primary, 
rather than adjunctive, treatment for low mood. However, 
recruiting a sample of unmedicated participants may have 
increased the overall treatment resistance of the sample, 
given that a majority of participants had received antide-
pressant medications prior to the study and still presented 
with significant, chronic low mood (self-report). There was 
an imbalance in prior antidepressant usage between the 
groups (more of the probiotic group had used antidepres-
sants in the past), which may indicate a higher level of 
treatment resistance among the probiotic group. Although 
controlling for the group difference in prior antidepressant 
usage had no effect on outcomes in this study, it is possible 
that the overall treatment resistance of the sample is not 
well represented by prior antidepressant use. We did not 
Table 6. Treatment-emergent adverse events reported by at 
least 5% of participants during the trial, by treatment group.
Probiotic 
group 
(n = 40)
Placebo 
group 
(n = 39) p
Constipation 7 11 0.29
Change in appetite 7 10 0.42
Nausea 6 7 0.77
Loss of libido 5 6 0.76
Weight gain 4 7 0.35
Dry mouth 2 8 0.048*
Nightmares 6 4 0.74
Abdominal pain 5 4 1.00
Anxiety 5 4 1.00
Urinary retention 5 4 1.00
Gastrointestinal 
disturbances
7 2 0.15
Headache 4 5 0.74
Agitation 4 3 1.00
Skin rash 4 2 0.68
Blurred vision 2 3 0.68
Inability to achieve orgasm 3 2 1.00
Sleep disruption 0 5 0.03*
Sedation/lethargy 1 3 0.36
*p < 0.05.
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formally assess treatment resistance; a standardized meas-
ure assessing treatment resistance (e.g. Antidepressant 
Treatment History Form; Sackeim, 2001) may have been 
valuable in interpreting the results of this trial.
Another potential confounder was that we allowed con-
current therapy on condition that the therapy had been 
ongoing for 6 months. This decision was taken on the basis 
of dose–response research that suggests that sudden 
improvements during long-term psychotherapy (more than 
15 sessions) are only as likely as spontaneous remission 
(see Hansen et al., 2002 for a review). Although it is possi-
ble that the inclusion of these participants may have skewed 
our results, we believe this is unlikely given that only 6 
participants (8%) were receiving concurrent psychother-
apy, and there was an equal number of these participants in 
each treatment group (any potential effect on study out-
comes was randomized out between the treatment groups).
The probiotic formulation used in this trial has shown 
positive effects on both emotional behaviour in animal 
studies (Arseneault-Breard et al., 2012; Messaoudi et al., 
2010) and psychological outcomes in a human study 
(Messaoudi et al., 2011). However, despite the existing evi-
dence to support the efficacy of the study product, it remains 
possible that different strains, more CFU or more strains 
combined into a single product may be more effective. It is 
important that the results of the current study are not gener-
alized to all potential probiotic strains.
Our exploratory analyses appear to show a moderating 
effect of vitamin D on treatment response. In the probiotic 
group, participants with high levels of vitamin D at the 
beginning of the study experienced significantly greater 
improvement on several psychological outcomes over time 
than those with low vitamin D at baseline. Baseline vitamin 
D had no effect on responding in the placebo group. Given 
the modulatory effects of vitamin D on the immune system 
(Battersby et al., 2012) and its role in immune cell develop-
ment and function (Griffin et al., 2003), it is possible that 
the vitamin D status of the host could have an effect on the 
relationship between the gut microbiota and the immune 
system: low vitamin D could limit response to probiotic 
treatment as any changes to the microbiome composition 
would not necessarily be translated to the immune system. 
Although this mechanism is unsupported by the lack of any 
significant effect of probiotics on inflammatory markers in 
the present study, it is possible that measuring markers of 
cell-mediated immunity may have been more appropriate. 
However, it is equally possible that there are other mecha-
nisms that we have yet to consider.
The current study assessed whether probiotics affect 
mood and other psychological outcomes when used as a pri-
mary treatment in a sample selected for low mood. This 
study has several limitations which should be addressed in 
future research. Measures of body mass index (BMI), body 
fat percentage, dietary intake and physical activity should be 
taken in future probiotics studies. The lack of intestinal 
microbiome analysis is a significant limitation of the current 
study, as we are unable to determine whether this probiotic 
formulation colonized effectively. It is possible that the lack 
of observed effect of probiotics on psychological outcomes 
is due to the size of the sample, the length of the intervention 
period, the severity, chronicity or treatment resistance of the 
sample, or the strains used. It is equally possible that probi-
otics are more appropriate as an adjuvant treatment for low 
mood or depression, as suggested by Logan and Katzman 
(2005). This is supported by the recent positive trial by 
Akkasheh et al. (2016) which showed that probiotics were 
beneficial to patients with MDD adjuvant to citalopram. 
Preventative trials giving probiotics to those at risk of gut 
dysbiosis (e.g. those born by caesarean section or bottle fed 
in infancy), which record any impact on mental health out-
comes in later life, may also prove valuable. Pärtty et al. 
(2015) provided probiotics or a placebo for 6 months in 
infancy and found a group difference in occurrences of 
attention-deficit/hyperactivity disorder (ADHD) and autism 
spectrum disorder (ASD) at 13 years of age. Early exposure 
to probiotics may also be protective for developing depres-
sion; further longitudinal studies are warranted.
In testing probiotics as a primary treatment for low mood, 
further studies testing different probiotic strains, for longer 
intervention periods and in different populations (e.g. less 
severe/chronic low mood, antidepressant-naive) are impor-
tant next steps in this very new area of research. Despite the 
lack of any observable effect of probiotics on psychological 
or biological outcomes in this study, future studies are strongly 
encouraged, and should take into account the findings of this 
study in relation to vitamin D, low levels of which could hin-
der the efficacy of probiotic supplements for low mood. The 
continued investigation of probiotics as a potential primary or 
adjuvant treatment for mood is especially important in light of 
the emerging research suggesting a novel biological aetiology 
of mood disorders, such as the relationship with inflamma-
tory/immune response and mitochondrial dysfunction (see 
Kaplan et al. (2015) for a review). The treatments outlined in 
the clinical practice guidelines for mood disorders recently 
published by the Royal Australian and New Zealand College 
of Psychiatrists (Malhi et al., 2015) adhere very much to the 
conventional model for treatment of mood disorders; this new 
understanding of the aetiology of mental disorders necessi-
tates a new paradigm for treatment. This area of research is in 
its infancy and, given the enormous burden of mood disorders 
on Western societies, the importance of continuing to explore 
the therapeutic potential of probiotics for low mood should 
not be underestimated.
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